Jeff Yass’s Actinium Pharmaceuticals ATNM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-13,100
| Closed | -$17.8K | – | 13131 |
|
|
2025
Q4 | $17.8K | Sell |
13,100
-4,100
| -24% | -$5.98K | ﹤0.01% | 11981 |
|
|
2025
Q3 | $27.5K | Buy |
+17,200
| New | +$28K | ﹤0.01% | 11991 |
|
|
2025
Q2 | – | Sell |
-10,700
| Closed | -$17.2K | – | 12616 |
|
|
2025
Q1 | $17.2K | Sell |
10,700
-3,700
| -26% | -$4.7K | ﹤0.01% | 12150 |
|
|
2024
Q4 | $18.1K | Buy |
+14,400
| New | +$22.3K | ﹤0.01% | 11932 |
|
|
2024
Q3 | – | Sell |
-41,300
| Closed | -$306K | – | 11922 |
|
|
2024
Q2 | $306K | Sell |
41,300
-53,500
| -56% | -$440K | ﹤0.01% | 9404 |
|
|
2024
Q1 | $742K | Buy |
94,800
+14,300
| +18% | +$91.9K | ﹤0.01% | 7577 |
|
|
2023
Q4 | $409K | Sell |
80,500
-200
| -0.2% | -$1.03K | ﹤0.01% | 9135 |
|
|
2023
Q3 | $478K | Buy |
80,700
+54,900
| +213% | +$365K | ﹤0.01% | 8332 |
|
|
2023
Q2 | $191K | Sell |
25,800
-59,900
| -70% | -$510K | ﹤0.01% | 10319 |
|
|
2023
Q1 | $810K | Buy |
85,700
+33,100
| +63% | +$349K | ﹤0.01% | 7377 |
|
|
2022
Q4 | $560K | Sell |
52,600
-78,000
| -60% | -$792K | ﹤0.01% | 7564 |
|
|
2022
Q3 | $964K | Sell |
130,600
-22,100
| -14% | -$137K | ﹤0.01% | 6719 |
|
|
2022
Q2 | $734K | Buy |
152,700
+85,400
| +127% | +$485K | ﹤0.01% | 7289 |
|
|
2022
Q1 | $344K | Sell |
67,300
-44,300
| -40% | -$233K | ﹤0.01% | 9922 |
|
|
2021
Q4 | $671K | Sell |
111,600
-96,600
| -46% | -$725K | ﹤0.01% | 8383 |
|
|
2021
Q3 | $1.84M | Buy |
208,200
+140,900
| +209% | +$980K | ﹤0.01% | 6010 |
|
|
2021
Q2 | $532K | Buy |
67,300
+2,400
| +4% | +$18.8K | ﹤0.01% | 9435 |
|
|
2021
Q1 | $495K | Buy |
64,900
+27,800
| +75% | +$236K | ﹤0.01% | 9496 |
|
|
2020
Q4 | $289K | Buy |
37,100
+26,800
| +260% | +$291K | ﹤0.01% | 9340 |
|
|
2020
Q3 | $100K | Buy |
10,300
+9,790
| +1,920% | +$108K | ﹤0.01% | 9914 |
|
|
2020
Q2 | $5K | Buy |
+510
| New | +$3.86K | ﹤0.01% | 10006 |
|
|
2017
Q4 | – | Sell |
-1,270
| Closed | -$22K | – | 9209 |
|
|
2017
Q3 | $22K | Sell |
1,270
-860
| -40% | -$18.9K | ﹤0.01% | 8638 |
|
|
2017
Q2 | $78K | Buy |
2,130
+1,060
| +99% | +$44.4K | ﹤0.01% | 8787 |
|
|
2017
Q1 | $48K | Buy |
+1,070
| New | +$41.1K | ﹤0.01% | 8599 |
|
|
2016
Q3 | – | Sell |
-537
| Closed | -$28K | – | 8366 |
|
|
2016
Q2 | $28K | Sell |
537
-136
| -20% | -$7.59K | ﹤0.01% | 8334 |
|
|
2016
Q1 | $40K | Buy |
+673
| New | +$42.5K | ﹤0.01% | 8710 |
|
|
2015
Q4 | – | Sell |
-357
| Closed | -$19K | – | 9388 |
|
|
2015
Q3 | $19K | Sell |
357
-1,386
| -80% | -$92.6K | ﹤0.01% | 9506 |
|
|
2015
Q2 | $139K | Sell |
1,743
-387
| -18% | -$33K | ﹤0.01% | 9528 |
|
|
2015
Q1 | $158K | Buy |
+2,130
| New | +$253K | ﹤0.01% | 8784 |
|
Other funds holding ATNM
CFM
GS
Jeff Yass's ATNM Position: Q2 2026 in Review
Jeff Yass reduced its Actinium Pharmaceuticals (ATNM) stake by 54% in Q2 2026, selling an estimated $77.6K and leaving 56,822 shares worth $55.7K. The position accounts for ﹤0.01% of the portfolio, ranked #12790.
Jeff Yass first reported a position in ATNM in Q2 2015 and has held it in 34 quarters since. The position peaked at $2.31M in Q1 2023. 47 funds tracked by Wall St. Rank hold ATNM as of Q2 2026.
- Jeff Yass held 56,822 shares of Actinium Pharmaceuticals worth $55.7K as of Q2 2026.
- Jeff Yass sold 67,176 Actinium Pharmaceuticals shares in Q2 2026, an estimated $77.6K.
- Actinium Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12790 holding.
- Jeff Yass first reported a position in Actinium Pharmaceuticals in Q2 2015 and has held it in 34 quarters since.
- Jeff Yass's Actinium Pharmaceuticals position peaked at $2.31M in Q1 2023.
- 47 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.